Table 2.
Baseline characteristics of enrolled patients
| Characteristic | Patients (n = 21) | Normal control (n = 18) | p value |
|---|---|---|---|
| Age at colonoscopy (yr) | 37.0 (26.5–58.0) | 51.5 (35.0–60.0) | 0.071 |
| Sex | 0.026 | ||
| Male | 15 (71.4) | 6 (33.3) | |
| Female | 6 (28.6) | 12 (66.7) | |
| Maximal disease extent before colonoscopy | |||
| Proctitis | 5 (23.8) | ||
| Left side colitis | 4 (19.0) | ||
| Extensive colitis | 12 (57.1) | ||
| Disease extent at colonoscopy | |||
| Proctitis | 12 (57.1) | ||
| Left side colitis | 4 (19.0) | ||
| Extensive colitis | 5 (23.8) | ||
| Disease activity | |||
| Remission (Mayo score 0-2) | 7 (33.3) | ||
| Mild (Mayo score 3-5) | 7 (33.3) | ||
| Moderate (Mayo score 3-5) | 7 (33.3) | ||
| MES | |||
| MES 0 | 6 (28.6) | ||
| MES 1 | 10 (47.6) | ||
| MES 2 | 4 (19.0) | ||
| MES 3 | 1 (4.8) | ||
| ESR at colonoscopy (mm/h) | 18.0 (9.5–31.5) | ||
| CRP at colonoscopy (mg/dL) | 0.25 (0.05–0.76) | ||
| Past medical history | |||
| 5-ASA | 20 (95.2) | ||
| Immunomodulator | 9 (42.9) | ||
| Anti-TNF agents | 6 (28.6) | ||
| Small molecules | 2 (9.5) | ||
| Follow-up duration (mo) | 152.0 (46.0–195.6) |
Values are presented as median (interquartile range) or number (%).
MES, Mayo endoscopic subscore; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; ASA, aminosalicylic acid; TNF, tumor necrosis factor.